Hepatitis/MASH

Military veteran tried to manage the symptoms of hepatitis C treatment before Harvoni cured him of the disease.

Research explores treatment of drug users with hepatitis C virus (HCV) infection with direct-acting antivirals.

Discovery holds promise for treatment of cirrhosis and liver damage related to hepatitis C.

The FDA has approved Gilead Sciences' supplemental new drug applications for ledipasvir/sofosbuvir (Harvoni), which can treat chronic hepatitis C patients with advanced liver disease.

New option approved for liver transplant patients and individuals with decompensated cirrhosis.

New option approved for liver transplant patients and individuals with decompensated cirrhosis.

Consuming less dietary cholesterol may reduce mortality or transplantation in women with hepatitis C.

Jon Hamrick, executive vice president, Biotech and Specialty Services at Therigy LLC, discusses the implications of rising drug costs on specialty pharmacy.

Most new cases of hepatitis C infection in New York City found in the baby boomer generation.

HCV transmission model predicts significant long term effect of direct-acting antivirals.

Zepatier is priced considerably lower with similar efficacy to Harvoni and Sovaldi.

Prohibitive cost to Medicaid for hepatitis C medications and high prices of generic and off-patent drugs evaluated.

Zepatier is priced considerably lower with similar efficacy to Harvoni and Sovaldi.

Coffee appears to confer a number of protective effects against liver disease.

Daklinza is a direct-acting antiviral agent for the treatment of hepatitis C virus.

Rapid intervention helps patient with hepatitis C avoid cirrhosis, carcinoma, and end-stage liver disease.

Treatment delivers miRNA to late-stage liver cancer tumors with low toxicity.

Michael Zeglinski, vice president of Specialty Pharmacy Operations at BriovaRx, discusses how expensive hepatitis C drugs have impacted the specialty landscape.

Study indicates nearly 12,000 deaths related to the liver could be prevented from routine HCV screenings.

Over the past 2 years, about 36 cases of acute hepatitis C virus infection were reported at 19 different hemodialysis clinics.

The FDA has approved Merck's elbasvir and grazoprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotypes 1 and 4 infections.

Zepatier is a once-daily, fixed-dose combination containing with the NS5A inhibitor elbasvir and the NS3/4A protease inhibitor grazoprevir.

Zepatier is a once-daily, fixed-dose combination containing with the NS5A inhibitor elbasvir and the NS3/4A protease inhibitor grazoprevir.

Researchers seek to predict age-related responses to hepatitis B vaccination.